Abstract
The present study was designed to evaluate the potential hypoglycemic and hypolipidemic effects of Angelica sinensis polysaccharide (ASP), purified from the fresh roots of Angelica sinensis (AS), in prediabetic and streptozotocin (STZ)-induced diabetic BALB/c mice. It was observed that fasting blood glucose (FBG) levels in both models were reduced after a 4-week oral administration of ASP or metformin, and abnormal fasting serum insulin (FINS) concentrations were ameliorated as well. Moreover, the homeostasis model assessment-insulin resistance (HOMA-IR) index was decreased strikingly and body weight (BW) was reduced significantly in prediabetic mice after treatment with ASP. In addition, ASP also contributed to improving the dyslipidemia conditions. Elevated serum total cholesterol (TC) or triglyceride (TG) concentrations were reduced after treatment with ASP in prediabetic mice or STZ-induced diabetic mice. Meanwhile, hepatic glycogen (HG) and muscle glycogen (MG) concentrations were increased while insulin resistance (IR)-related inflammatory factors IL-6 and TNF-α in serum were reduced in STZ-induced diabetic mice. Histopathological examination indicated that the impaired pancreatic/hepatic tissues or adipose tissues were effectively restored in STZ-induced diabetic mice or prediabetic mice after the ASP treatment. Taken together, these results revealed that ASP efficiently exerted hypoglycemic and hypolipidemic benefits, and its potential effect was associated with the amelioration of IR. ASP can be applied in the prevention and treatment of diabetes.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adipose Tissue, White / immunology
-
Adipose Tissue, White / metabolism
-
Adipose Tissue, White / pathology
-
Angelica sinensis / chemistry*
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / isolation & purification
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Diabetes Mellitus, Type 2 / diet therapy*
-
Diabetes Mellitus, Type 2 / immunology
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetes Mellitus, Type 2 / pathology
-
Glycogen / agonists
-
Glycogen / metabolism
-
Hyperglycemia / prevention & control
-
Hyperinsulinism / prevention & control
-
Hyperlipidemias / prevention & control
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / isolation & purification
-
Hypoglycemic Agents / therapeutic use*
-
Hypolipidemic Agents / administration & dosage
-
Hypolipidemic Agents / isolation & purification
-
Hypolipidemic Agents / therapeutic use
-
Insulin Resistance
-
Lipid Metabolism Disorders / prevention & control*
-
Liver / immunology
-
Liver / metabolism
-
Liver / pathology
-
Male
-
Mice, Inbred BALB C
-
Muscle, Skeletal / immunology
-
Muscle, Skeletal / metabolism
-
Pancreas / immunology
-
Pancreas / metabolism
-
Pancreas / pathology
-
Plant Roots / chemistry*
-
Polysaccharides / administration & dosage
-
Polysaccharides / isolation & purification
-
Polysaccharides / therapeutic use*
-
Prediabetic State / diet therapy*
-
Prediabetic State / immunology
-
Prediabetic State / metabolism
-
Prediabetic State / pathology
-
Random Allocation
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Hypoglycemic Agents
-
Hypolipidemic Agents
-
Polysaccharides
-
Glycogen